secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001396814-25-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira preliminary FY2024 revenue $701M (+3.9% YoY); announces 5x30 growth plan
-------------------------------------------------------------------------------

- FY2024 total revenue of $701.0M, up from $675.0M in 2023; Q4 EXPAREL $147.7M.
- EXPAREL net sales $549.0M, ZILRETTA $118.1M, iovera° $22.8M for full year.
- Unveils 5x30 plan: treat >3M patients/year, double-digit revenue CAGR, 5pp gross margin improvement by 2030.
- Inducement grants: options for 20,300 shares and RSUs for 30,400 shares at $18.40.
- Revenue preliminary and unaudited; full Q4 and FY results with guidance expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000011/0001396814-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681425000011/pcrx-20250110.htm
  HTML page:      https://secwatch.observer/filing/0001396814-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer